News & Events
Probiodrug to present at US and Japanese Conferences
Published: 15 October 2015

 Probiodrug to present at US and Japanese Conferences

HALLE/SAALE, Germany, 15 October 2015 - Probiodrug AG ("Probiodrug", Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease, announces that Dr Hendrik Liebers, Chief Financial Officer, is scheduled to present at the following events:

(1) BIO Investor Forum
20 - 21 October 2015, Parc 55 San Francisco - A Hilton Hotel, San Francisco, US

Dr Hendrik Liebers, CFO, to present on 20 October at 8.00 am PDT in room Fillmore

BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and one-on-one Partnering meetings. BIO Investor Forum has showcased more than 600 leading companies to hundreds of investment and pharma business development professionals.

(2) Sofinnova Japan BioPharma Partnering Conference
27 October 2015, Conrad Hotel, Tokyo, Japan

Dr Hendrik Liebers, CFO, to present on 27 October at 12.05 pm JST in room Nami

In its eighth year, the Sofinnova Japan Biopharma Partnering Conference brings together premier biotechnology companies from North America and Europe with influential Japanese licensing and business development executives. Attendees can engage in company presentations, one-on-one partnering meetings and industry discussions.


For more information, please contact:

Dr Konrad Glund, CEO
Hume Brophy
Mary Clark, Supriya Mathur, Alexia Faure
Tel: +44 (0) 203 440 5657

Notes to Editors:

About Probiodrug AG
Headquartered in Halle, Germany, Probiodrug AG (Euronext Amsterdam: PBD) is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer's disease.

Founded in 1997, the company successfully developed a novel therapeutic concept for diabetes - the DP4 inhibitors - which provided the basis for a novel class of antidiabetics - the gliptins. Its core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes involved in the modification of proteins and peptides, which play a central role in pathological conditions.

Today Probiodrug's aim is to become a leading company in the development of Alzheimer's disease treatments and to thereby provide a better life for Alzheimer's disease patients. It has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight Alzheimer's disease. The Company has medical use and composition of matter patents related to the inhibition of Glutaminyl Cyclase (QC) and anti-pGlu-Abeta- specific monoclonal antibodies, providing it, in the Company's view, with a leading position in this field of research.

About Alzheimer's disease
Alzheimer's disease is a neurological disorder, which is the most common form of dementia, and ultimately leads to death. Because Alzheimer's disease cannot be cured and is degenerative, the affected patients must increasingly rely on others for assistance. Today, 44 million people worldwide currently live with the condition and this number is expected to almost double by 2030 and to more than triple by 2050 to over 132 million. Alzheimer's also has an estimated, global societal cost of over $600 billion (World Alzheimer Report 2014).

Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Probiodrug AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.